Other Head and Neck Sites

  • Gregory D. Judy
  • Bhishamjit S. Chera


There is minimal to no data regarding the use of SBRT as definitive primary treatment in other head & neck disease sites. Limited data support the use of brachytherapy or SBRT as a boost to EBRT in the definitive setting for nasopharyngeal (Chap. 1), paranasal sinus, and oropharyngeal SCC.
  • Generally indicated for T1-2 tumors.

  • Efficacy and complication rates are similar between brachytherapy and SBRT.


Head and neck SBRT Treatment boost 


  1. 1.
    Al-Mamgani A, Van Rooij P, Sewnaik A, et al. Brachytherapy or stereotactic body radiotherapy boost for early-stage oropharyngeal cancer: comparable outcomes of two different approaches. Oral Oncol. 2013;49:1018–24.CrossRefPubMedGoogle Scholar
  2. 2.
    Lee DS, Kim YS, Cheon JS, et al. Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment. Radiat Oncol. 2012;7:85.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Gregory D. Judy
    • 1
    • 2
  • Bhishamjit S. Chera
    • 1
    • 2
  1. 1.Department of Radiation OncologyUniversity of North Carolina School of MedicineChapel HillUSA
  2. 2.Lineberger Comprehensive Cancer CenterUniversity of North Carolina School of MedicineChapel HillUSA

Personalised recommendations